First national guideline recommendation for Shield paves the way for improved patient access and additional major guideline inclusions
Guardant Health, a leading precision oncology company, announced that the National Comprehensive Cancer Network has included the Shield blood test in its updated colorectal cancer screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA). The updated NCCN CRC Screening Guidelines reflect the addition of Shield with a recommendation for testing every three years.
Health Technology Insights: Simplex Quantum Selected for MedTech Innovator Asia Pacific 2025
“With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of eligible Americans who are forgoing their recommended screening for colorectal cancer,” said AmirAli Talasaz, Guardant Health co-CEO. “This major guideline inclusion from the National Comprehensive Cancer Network is just the first for Shield, and we believe a pivotal step for more patients to benefit from this test.”
In its guideline update, the NCCN pointed to Guardant’s landmark ECLIPSE (Evaluation of ctDNA LUNAR Assay in an Average Patient Screening Episode) study evaluating the performance of Shield compared to a screening colonoscopy. One of the largest studies of its kind and published in the New England Journal of Medicine (NEJM), ECLIPSE demonstrated that the Shield blood test is highly effective in detecting CRC, with a sensitivity of 83 percent.
Health Technology Insights: UNA Health Unveils UNA AIR to Revolutionize Healthcare Remediation
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
